| New vaccine chief rocks pharmaceutical stocks |
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump. |
youtube.com |
2025-05-07 15:13:02 |
Czytaj oryginał (ang.) |
| Why BioNTech Stock Got Trounced on Tuesday |
An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (BNTX -6.58%). Investors were concerned about the latest top-level appointment in public health, plus an analyst became a bit more bearish about the company's future. |
fool.com |
2025-05-06 22:15:41 |
Czytaj oryginał (ang.) |
| BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade) |
BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares dropped after competitor's interim data disappointed investors. Increased regulatory scrutiny under Kennedy's HHS creates uncertainty for mRNA technologies, prompting a downgrade from Buy to Hold. |
seekingalpha.com |
2025-05-06 11:45:00 |
Czytaj oryginał (ang.) |
| BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion |
BioNTech SE BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02. |
benzinga.com |
2025-05-05 19:49:24 |
Czytaj oryginał (ang.) |
| BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript |
BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Officer Özlem Türeci - Co-Founder & Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Daina Graybosch - Leerink Partners Cory Kasimov - Evercore Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Evan Seigerman - BMO Capital Markets Yaron Werber - TD Cowen Mohit Bansal - Wells Fargo Harry Gillis - Berenberg John Newman - Canaccord Genuity Operator Welcome to BioNTech's First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations. |
seekingalpha.com |
2025-05-05 15:39:36 |
Czytaj oryginał (ang.) |
| BioNTech Announces First Quarter 2025 Financial Results and Corporate Update |
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion 2 , net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial position with €15.9 billion in cash, cash equivalents and security investments as of March 31, 20254 Full year 2025 financial guidance confirmed Conference call and webcast scheduled for May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. |
globenewswire.com |
2025-05-05 10:45:00 |
Czytaj oryginał (ang.) |
| BioNTech says Novartis executive Zapata-Gomez to become CFO |
German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1. |
reuters.com |
2025-05-05 10:34:19 |
Czytaj oryginał (ang.) |
| BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer |
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025. |
globenewswire.com |
2025-05-05 10:30:00 |
Czytaj oryginał (ang.) |
| Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today |
Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading. |
fool.com |
2025-04-25 21:05:19 |
Czytaj oryginał (ang.) |
| BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 |
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech's advanced priority oncology programs as well as the execution of the Company's combination strategy in oncology, with first data to be presented for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT3271 plus antibody-drug conjugates (“ADCs”). |
globenewswire.com |
2025-04-24 10:45:00 |
Czytaj oryginał (ang.) |
| BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025 |
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. |
globenewswire.com |
2025-04-22 10:45:00 |
Czytaj oryginał (ang.) |
| Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? |
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-04-15 14:05:44 |
Czytaj oryginał (ang.) |
| Vaccine stocks fall following FDA resignation |
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more. |
youtube.com |
2025-03-31 22:21:01 |
Czytaj oryginał (ang.) |
| Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views |
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization. |
fastcompany.com |
2025-03-31 18:41:33 |
Czytaj oryginał (ang.) |
| Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul |
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies. |
nypost.com |
2025-03-31 18:25:42 |
Czytaj oryginał (ang.) |
| Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. |
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F. |
cnbc.com |
2025-03-31 14:13:15 |
Czytaj oryginał (ang.) |
| Biotech stocks tumble on reports FDA's top vaccine regulator to leave |
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments. |
reuters.com |
2025-03-31 11:25:25 |
Czytaj oryginał (ang.) |
| Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen |
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Metastatic Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Metastatic Melanoma. Refractory Metastatic Melanoma Emerging Drugs Chapters This segment of the Refractory Metastatic Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Refractory Metastatic Melanoma Emerging Drugs |
globenewswire.com |
2025-03-20 15:36:00 |
Czytaj oryginał (ang.) |
| BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment |
BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent ruling, remain pending, which poses short-term headwinds. Nevertheless, BNTX's robust balance sheet makes it cheap relative to its long-term potential. It also de-risks the company until it refocuses on oncology. |
seekingalpha.com |
2025-03-17 10:45:00 |
Czytaj oryginał (ang.) |
| BioNTech SE (BNTX) Q4 2024 Earnings Call Transcript |
BioNTech SE (NASDAQ:BNTX ) Q4 2024 Earnings Conference Call March 10, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder and Chief Executive Officer Ozlem Tureci - Co-Founder and Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Tazeen Ahmad - Bank of America Securities Terence Flynn - Morgan Stanley Harry Gillis - Berenberg Cory Kasimov - Evercore Sadia Rahman - Wells Fargo Asthika Goonewardene - Truist Securities Yaron Werber - TD Cowen Jessica Fye - JP Morgan Operator Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. |
seekingalpha.com |
2025-03-10 14:14:22 |
Czytaj oryginał (ang.) |
| FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled |
A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month. |
forbes.com |
2025-02-27 04:53:56 |
Czytaj oryginał (ang.) |
| Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus |
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic. |
zacks.com |
2025-02-24 11:30:27 |
Czytaj oryginał (ang.) |
| BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025 |
MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. |
globenewswire.com |
2025-02-24 08:45:00 |
Czytaj oryginał (ang.) |
| What Makes BioNTech (BNTX) a New Buy Stock |
BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-13 15:01:23 |
Czytaj oryginał (ang.) |
| Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job |
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel. |
reuters.com |
2025-02-04 13:51:44 |
Czytaj oryginał (ang.) |
| Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary |
Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber. |
cnbc.com |
2025-02-04 13:50:33 |
Czytaj oryginał (ang.) |
| BioNTech Completes Acquisition of Biotheus |
MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates. |
globenewswire.com |
2025-02-03 08:45:00 |
Czytaj oryginał (ang.) |
| 3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection |
How expensive is the stock market right now? The S&P 500 Shiller CAPE ratio is near its second-highest level ever. |
fool.com |
2025-01-22 06:52:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-17 12:56:14 |
Czytaj oryginał (ang.) |
| BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference |
MAINZ, Germany, January 14, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today will present its 2025 strategic priorities and progress on the Company's pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. |
globenewswire.com |
2025-01-14 08:45:00 |
Czytaj oryginał (ang.) |
| Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 |
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions. |
seekingalpha.com |
2025-01-13 20:10:02 |
Czytaj oryginał (ang.) |
| BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst |
On Thursday, Truist initiated coverage on BioNTech SE BNTX, a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc PFE. |
benzinga.com |
2025-01-10 16:54:55 |
Czytaj oryginał (ang.) |
| BioNTech initiated with a Buy at Truist |
Truist initiated coverage of BioNTech with a Buy rating and $172 price target. BioNTech is an oncology company "at heart, even though it was the COVID vaccine that made it a household name," the analyst tells investors in a research note. The firm says that with the pandemic in the rear-view mirror, investor focus is increasingly shifting to BioNTech's oncology business. It says 2025 is set up with potentially stock-moving read-outs for key assets, presenting "ample opportunity" for BioNTech to grow into the price target. |
https://thefly.com |
2025-01-09 22:49:44 |
Czytaj oryginał (ang.) |
| 5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right |
Nearly one year ago, I made four predictions about the stock market in 2024. I thought the S&P 500 would generate positive returns but lower than in 2023. |
fool.com |
2025-01-04 07:46:00 |
Czytaj oryginał (ang.) |
| BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties |
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine, the company said in filings on Friday. |
reuters.com |
2024-12-27 09:54:52 |
Czytaj oryginał (ang.) |
| 3 No-Brainer Biotech Stocks to Buy With $200 Right Now |
Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs. |
fool.com |
2024-12-18 07:44:00 |
Czytaj oryginał (ang.) |
| US FDA lifts partial clinical hold on BioNTech cancer drug study |
BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a type of lung cancer. |
reuters.com |
2024-12-13 18:12:26 |
Czytaj oryginał (ang.) |
| 2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid |
I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond. |
fool.com |
2024-12-11 07:50:00 |
Czytaj oryginał (ang.) |
| 2 No-Brainer Stocks to Buy Before the End of 2024 |
I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion. |
fool.com |
2024-12-09 07:50:00 |
Czytaj oryginał (ang.) |
| Why Is BioNTech Stock Trading Higher On Friday? |
On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE BNTX. |
benzinga.com |
2024-12-06 15:14:49 |
Czytaj oryginał (ang.) |
| 5 Top Stocks to Buy in December |
The end of the year can spur myriad feelings when deciding which stocks are the best buys. |
fool.com |
2024-12-04 07:45:00 |
Czytaj oryginał (ang.) |
| BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It. |
Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line. |
barrons.com |
2024-11-19 13:57:00 |
Czytaj oryginał (ang.) |
| Analysts Turn Bullish on BioNTech Stock Amid Volatility |
BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line. |
schaeffersresearch.com |
2024-11-19 12:19:27 |
Czytaj oryginał (ang.) |
| BioNTech and Moderna at vanguard of new treatment wave - but which is best? |
The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases. |
proactiveinvestors.co.uk |
2024-11-19 07:14:00 |
Czytaj oryginał (ang.) |
| Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head |
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services. |
investopedia.com |
2024-11-15 14:55:46 |
Czytaj oryginał (ang.) |
| European And US Vaccine Stocks Are Under Pressure - Here's WHy |
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. |
benzinga.com |
2024-11-15 13:21:18 |
Czytaj oryginał (ang.) |
| BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up |
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications. |
zacks.com |
2024-11-14 13:45:27 |
Czytaj oryginał (ang.) |
| BioNTech buys China's Biotheus to support oncology strategy |
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday. |
reuters.com |
2024-11-13 08:52:11 |
Czytaj oryginał (ang.) |
| BioNTech to Acquire Biotheus to Boost Oncology Strategy |
MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. |
globenewswire.com |
2024-11-13 08:45:00 |
Czytaj oryginał (ang.) |
| BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential |
Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. |
benzinga.com |
2024-11-09 16:12:49 |
Czytaj oryginał (ang.) |
| BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold |
BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved revenues and profit, largely driven by its COVID-19 vaccine, Comirnaty, which remains a significant revenue source. Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a “Hold” rating. |
seekingalpha.com |
2024-11-06 13:53:28 |
Czytaj oryginał (ang.) |
| BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript |
BioNTech SE (NASDAQ:BNTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Daina Graybosch - Leerink Partners Suzanne van Voorthuizen - VLK Terence Flynn - Morgan Stanley Yaron Werber - TD Cowen Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Luke Shumway - BMO Capital Markets Ellie Merle - UBS Yifeng Liu - HSBC Bank Plc Simon Baker - Redburn Atlantic Manos Mastorakis - Deutsche Bank Jay Olson - Oppenheimer Operator Welcome to BioNTech's Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. |
seekingalpha.com |
2024-11-04 15:05:27 |
Czytaj oryginał (ang.) |
| BioNTech surprises with Q3 profit driven by strong vaccine sales |
BioNTech SE reported a surprising profit for the third quarter, achieving earnings of €0.81 ($0.88) per diluted share, far exceeding analyst expectations of a loss of €1.84. The Mainz, Germany-based company also posted sales of €1.2 billion, nearly three times higher than anticipated. |
proactiveinvestors.com |
2024-11-04 13:48:52 |
Czytaj oryginał (ang.) |